David Graff, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2180 Main St, Wailuku, HI 96793 Phone: 808-242-6464 Fax: 808-242-4210 |
Kimberly Kowalski, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 221 Mahalani St, Wailuku, HI 96793 Phone: 808-442-5503 Fax: 808-442-5512 |
Zora Bulatovic, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2180 Main St, Wailuku, HI 96793 Phone: 808-242-6464 Fax: 808-242-4292 |
Andrew Sumida, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 221 Mahalani St, Wailuku, HI 96793 Phone: 808-442-5503 Fax: 808-442-5512 |
Cedric J Strong, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2180 Main St, Wailuku, HI 96793 Phone: 808-242-6464 Fax: 808-242-4292 |
Dr. Mazin Mahgoub Noor, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 221 Mahalani St, Wailuku, HI 96793 Phone: 808-442-5503 |
News Archive
BSD Medical Corp. has filed a patent for a new non-invasive phased array breast treatment applicator developed to selectively heat breast cancer tumors.
Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.
"A top United Nations relief official who just returned from a trip to northern Mali said Tuesday that desperation, hunger and fear had pervaded the region in the year since Islamist militant extremists seized control, and that only $17 million of the organization's appeal for $373 million in emergency aid had been donated so far," the New York Times reports.
Opioids and selective serotonin reuptake inhibitors, a widely used group of antidepressants, are both associated with higher risk of osteoporotic fractures for patients with rheumatoid arthritis, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.
› Verified 2 days ago